2021
Application for quotation of securities
02/08/2021Exercise of Options and Secondary Trading Notice
30/07/2021Appendix 4C – June 2021 Quarterly Update
28/07/2021Manufacturing update and clarification of Abcam engagement
22/07/2021Proteomics International engages Abcam to manufacture PromarkerD reagents
20/07/2021Investor Presentation
16/07/2021Diabetes treatment lowers PromarkerD risk score: Results to be presented at Australasian Diabetes Conference
02/07/2021Update on study presented at ADA Conference
28/06/2021World-first predictive test for Diabetic Kidney Disease could save $384 billion over 10 years
10/06/2021CCO and CFO appointed to bolster executive team
18/05/2021Proteomics secures major analytical services contract
13/05/2021Study demonstrates major economic health benefit of PromarkerD – PromarkerD reimbursement update
30/04/2021Proposed issue of Securities
30/04/2021Issue of Options and Secondary Trading Notice
29/04/2021Appendix 4C – March 2021 Quarterly Update
29/04/2021Proteomics files US FDA 513(g) regulatory submission
23/04/2021Proteomics International achieves ISO 13485 certification
15/03/2021Exercise of Options
09/03/2021Investor Presentation
26/02/2021Exercise of Options
25/02/2021Appendix 4D and Interim Financial Report
16/02/2021Response to Price Query
08/02/2021Proteomics International seeks FDA approval for PromarkerD
28/01/2021Update – Proposed issue of Securities – PIQ
28/01/2021Issue of Options and Secondary Trading Notice
28/01/2021Results of Meeting
28/01/2021Appendix 4C – December 2020 Quarterly Update
